Tickers

Vivos Inc.'s IsoPet® cancer therapy reports record Q1 2025 growth with 150% more treatments, new clinic certifications, and expanded therapeutic applications.

Vivos Inc. reports major progress in its India human trial for RadioGel®, showing high safety and localized tumor treatment precision.

Vivos Inc. Expands IsoPet® Animal Cancer Division in 2025 Vivos Inc. (OTCQB: RDGL) strengthens its IsoPet® division in 2025 with the expansion of clinics, training advancements, and cutting-edge cancer treatments for pets Vivos Inc. (OTCQB: RDGL) continues to make remarkable progress...

Vivos Inc. advances cancer treatment with RadioGel® PRnT™ Human trials in India show early success, with Mayo Clinic expansion planned in 2025.

U.S. policies like 45Z and the Farm-to-Fly Act are failing farmers and ethanol producers, giving Brazil a possible global edge in SAF production.

BioLargo's recent financials and corporate updates highlight continued growth of its AEC PFAS-removal technology soon to be operational at commercial scale.